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Abstract
Background. Antidepressant medications (ADMs) are widely used and long-term use is
increasing. Given this extensive use and recommendation of ADMs in guidelines, one would
expect ADMs to be universally considered effective. Surprisingly, that is not the case; fierce
debate on their benefits and harms continues. This editorial seeks to understand why the
controversy continues and how consensus can be achieved.
Methods. ‘Position’ paper. Critical analysis and synthesis of relevant literature.
Results. Advocates point at ADMs impressive effect size (number needed to treat, NNT = 6–8)
in acute phase treatment and continuation/maintenance ADM treatment prevention relapse/
recurrence in acute phase ADM responders (NNT = 3–4). Critics point at the limited clinically
significant surplus value of ADMs relative to placebo and argue that effectiveness is overstated.
We identified multiple factors that fuel the controversy: certainty of evidence is low to mod-
erate; modest efficacy on top of strong placebo effects allows critics to focus on small net
efficacy and advocates on large gross efficacy; ADM withdrawal symptoms masquerade as
relapse/recurrence; lack of association between ADM treatment and long-term outcome in
observational databases. Similar problems affect psychological treatments as well, but less so.
We recommend four approaches to resolve the controversy: (1) placebo-controlled trials with
relevant long-term outcome assessments, (2) inventive analyses of observational databases,
(3) patient cohort studies including effect moderators to improve personalized treatment,
and (4) psychological treatments as universal first-line treatment step.
Conclusions. Given the public health significance of depression and increased long-term
ADM usage, new approaches are needed to resolve the controversy.
Introduction
Antidepressant medications (ADMs) are widely prescribed and maintenance of ADM treat-
ment is increasing. In the USA, 12% of the population 12 years and older utilize ADMs,
and the percentage using ADMs ⩾24 months more than doubled from 3% to 7% between
1999 and 2010 (Mojtabai & Olfson, 2014; Pratt, Brody, & Gu, 2017). Similar trends have
been observed in the UK (Lockhart & Guthrie, 2011) and the Netherlands (Wildeboer, van
der Hoek, & Verhaak, 2016). Given this utilization, the hundreds of double-blind placebo-
controlled AD trials (Cipriani et al., 2018), and the prominent recommendation of ADMs
in clinical guidelines, one would expect that ADMs are universally considered effective and
worth their side effects. Surprisingly, that is not the case: fierce debate on their effectiveness
continues in the scientific literature, media, and Internet (Moncrieff, 2018a). Here we explore
the positions of the advocates and critics and examine why the debate continues and how it is
best resolved. In addition, we examine the efficacy of evidence-based psychological treatments
and their vulnerability to criticism.
Advocates point at the significant effect size of acute phase ADM treatment (aADM) of
depression [number needed to treat (NNT) = 6–8], the ability of continuation and mainten-
ance antidepressants (cmADs) to prevent relapse/recurrence in those who remit on aADM
(NNT = 3–4), and the reduced risk of suicide (attempts) associated with ADM treatment
(Bridge, Barbe, Birmaher, Kolko, & Brent, 2005; Cooney et al., 2013; Geddes & Cipriani,
2015; Leucht, Hierl, Kissling, Dold, & Davis, 2012; Nutt, Goodwin, Bhugra, Fazel, & Lawrie,
2014; Quitkin, Rabkin, Gerald, Davis, & Klein, 2000). Advocates acknowledge individual
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differences in response and that many do not respond to ADMs
as well as significant side effects and dropouts. However, they
argue that most patients on cmADM choose to stay on ADMs,
suggesting that the benefits prevail, and that good clinical man-
agement can keep dropouts and adverse side effects low.
Critics doubt whether antidepressants have clinically signifi-
cant surplus value over and above placebo (PLA) (Antonuccio,
Danton, DeNelsky, Greenberg, & Gordon, 1999; Fava, 2003;
Gotschke, 2013; Kirsch, 2014; Kirsch et al., 2008; Moncrieff,
2002, 2018b; Moncrieff & Kirsch, 2015; Turner, Matthews,
Linardatos, Tell, & Rosenthal, 2008; Whitaker, 2015). The
standardized mean difference (SMD) observed in recent
meta-analyses is ∼0.3 (Cipriani et al., 2018). On average, this
translates to 2–3 points more on the Hamilton Depression
Rating Scale (HAMD) than the reduction seen with placebo, a
group difference that critics have argued is clinically insignificant
(Moncrieff & Kirsch, 2015). Critics argue that trials (and thus
meta-analyses) overestimate effectiveness due to a variety of
biases, owing to unblinding, high dropout rates, selective patient
recruitment, publication bias, etc. (Turner et al., 2008). They
point at the heavy marketing and manipulation of research data
by the pharmaceutical industry and the many conflicts of interest
of ADM advocates (Gotschke, 2013; Whitaker, 2015).
Unfortunately, both advocates and critics selectively cite
studies in support of their positions but hardly address and ana-
lyze the evidence cited by the other side, with some exceptions
(Quitkin et al., 2000). A nice illustration is provided by the cita-
tions on efficacy and suicide risk provided by Nutt et al. (2014)
and Gotzsche (2014) in their 2014 letters in the Lancet on benefits
and harms of ADMs. Such discussions remain sterile and do not
advance knowledge. They benefit neither patients nor providers.
Methods
Our editorial is not a systematic review or meta-analysis but rather
a logical conceptual and methodological analysis. We address two
important issues: why have antidepressants become so widely
prescribed and how valuable are antidepressants in the treatment
of depression. Both have multiple facets. It is virtually impossible
(and largely irrelevant to what we set out to do) to address each
facet in a full systematic way or by meta-analysis. A fully system-
atic approach would have required many literature searches, and
would probably result in multiple papers. What we chose to do
was to think rather than to count. We think that there is value
in a logical analysis. While we have done our best to use system-
atic reviews and meta-analyses to inform our thinking as much as
possible, what we set out to do was to describe where we thought
the field currently is and where it ought to go. We have tried to be
balanced in our selection of literature and to describe studies
systematically.
Factors that keep fueling the dispute
Acute phase ADM trials: efficacy and limitations
Response rates (symptom reduction of 50% or more from base-
line) in aADM arms exceed those in PLA arms, typically by
10–15%. The largest recent meta-analysis of aAD efficacy by
Cipriani et al. included 522 trials, published and unpublished,
comprising 1 16 477 participants and found that ADs had better
response rates than placebo, with ORs ranging between 1.37
and 2.13 and an averaged SMD = 0.30, similar to NNT = 8
(Meadows et al., 2019), comparable with other recent meta-analyses
(Cipriani et al., 2018). Although treatment settings were often
unclear, most trials did not take place in primary care settings.
Cipriani et al.’s meta-analysis may even underestimate antide-
pressants efficacy as post-hoc analyses have found consistent
superiority and dose-dependency for selective serotonin reuptake
inhibitors (SSRIs) relative to PLA when using depressed mood as
the major outcome (Hieronymus, Emilsson, Nilsson, & Eriksson,
2016a; Hieronymus, Nilsson, & Eriksson, 2016b) or the six proto-
typical depression items from the HAMD [depressed mood, guilt
feeling, loss of interests, psychomotor retardation, psychic anxiety,
and tiredness (Bech, 2010)]. The dose-dependency figures suggest
that inclusion of trials using suboptimal doses in Cipriani et al.’s
meta-analyses may have led to an underestimation of aADM
efficacy. Likewise, the use of more narrow depression symptoms
might have yielded higher efficacies, although caution is needed
given the post-hoc nature of these findings. Because it is not
fully clear whether findings from specialty settings can be general-
ized to primary care as only a minority of cases are referred to
specialty settings, Linde et al. meta-analyzed 66 randomized con-
trolled trials (RCTs) with 15.161 patients treated in primary care
(Linde et al., 2015). ADs were found to be significantly superior to
PLA, with estimated ORs between 1.69 and 2.03, rather similar to
the Cipriano results. There were no significant differences between
drug classes. Compared to general medicine drugs (e.g. ACE inhibi-
tors and statins for prevention of cardiovascular events and stroke)
ADM are not in general less efficacious (Leucht et al., 2012),
although the clinical significance of a given effect size is context-
dependent and may differ between psychiatry and general medicine.
Such data should settle the debate, at least for the acute phase
treatment. However, a few issues still produce uncertainties. First,
the authors caution that the ‘certainty of evidence was moderate
to very low’ with ‘46 (9%) of 522 trials rated as high risk of
bias, 380 (73%) as moderate, and 96 (18%) as low’ (p. 1), leaving
space for speculation about bias. Second, the analysis did not
address full remission efficacy, only response, i.e. 50% or more
improvement relative to baseline. That is, patients were better
but not necessarily well. Third, the modest SMD, corresponding
to a few HAMD points, has been argued to be of limited clinical
significance (Jakobsen et al., 2017; Kirsch, 2014; Moncrieff &
Kirsch, 2015; Turner et al., 2008). Fourth, it remains unclear
how large the risk of breaking the blind is in SSRI trials because
they have no ‘active’ placebo. Side effects of TCAs can be mim-
icked and a meta-analysis comparing TCA and active placebos,
though limited by methodological problems found no significant
difference (Moncrieff, 2003). These limitations keep providing
fuel for critics.
Prolonged acute phase trials: 6–8 months outcomes
Some acute phase placebo-controlled trials have prolonged
follow-up assessments of response and remission up to 8 months
post-baseline randomization. Deshauer et al.’s meta-analysis
included six studies that randomized a total of 1299 patients to
either ADM or PLA and followed both groups for 6–8 months
(Deshauer et al., 2008). Response rates averaged 61% in the
ADM and 48% in the PLA arm, a difference of 13%; rates for
remission, assessed in only four trials, were 45% and 38%, a dif-
ference of 7%, yielding a non-significant trend ( p < 0.1). It is
important to note that at least half of the studies (Davidson
et al., 2002; Detke et al., 2004; Murray et al., 2005) included in
Deshauer et al.’s meta-analysis excluded patients from follow-up
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if they did not respond to the acute phase blinded treatment, even
if their short-term data were used in the intention-to-treat ana-
lysis. It is unclear whether similar exclusions occurred in the
other three studies. Differences in treatment dropouts and study
completers were not significant between the arms but many par-
ticipants did not complete the final outcome assessment, ranging
from 23% to 73% with mean 52% (Deshauer et al., 2008). The
studies evidenced moderate risk of bias and most failed to report
key methodologic issues, for instance on what happened to those
who did not improve during the acute phase. Hence it is unclear
how valid and generalizable the results of these prolonged aADM
trials are. Compared to remission rates in the 8–12 week trials,
Deshauer et al.’s findings suggest that the placebo group tends
to ‘catch up’, possibly due to the natural history of depression.
Placebo effects and spontaneous remission; net and gross
efficacy
Response rates (⩾50% improvement) in PLA arms of RCTs
of depression are large, often between 35% and 40% in the
PLA arm (Furukawa et al., 2016; Levkovitz, Tedeschini, &
Papakostas, 2011; Rutherford & Roose, 2013). The response in
PLA arms is due to multiple factors: (i) spontaneous remission
referring to the phenomenon that some people get better in the
absence of any treatment as part of the natural course of their
depression; (ii) regression to the mean, in which individuals
who are far from the mean at the baseline measurement tend to
be closer to the mean at the next measurement, in as far as
their extreme baseline scores were inflated by measurement
error; and (iii) non-specific treatment effects, which consist of
improvement due to being treated by a professional including
explanation, attention, support, positive expectations, amongst
others. It is possible that the placebo response in ADM trials is
larger than with real-world patients because patients in regulatory
trials are not fully representative of real-world patients (Rush
et al., 2006; Van der Lem, van der Wee, Van Veen, & Zitman,
2012). The large placebo effect indicates that many respond not
because of the specific ADM treatment, but because of other
effects. This makes it difficult for trials to establish the excess
value of specific treatments and provides critics with ammunition
to minimize the benefits of ADMs by focusing on net efficacy and
advocates to maximize benefits by focusing on gross efficacy.
Continuation and maintenance ADM trials: efficacy and
limitations
The most recent meta-analysis evaluated 72 cADM and 37
mADM trials with 14.450 and 7253 participants, respectively
(Sim, Lau, Sim, Sum, & Baldessarini, 2016). In the 72 cADM
trials, lasting 33 weeks on average, the pooled advantage of
cADM over discontinuation to placebo in terms of the relative
response rate (RR) was 1.90, CI 1.73–2.08, NNT 4.4; in the 37
mADM trials lasting 27 months on average, it was 2.03, CI
1.80–2.28; NNT = 3.8; with minor differences among drug types
(Sim et al., 2016). The authors did not distinguish between the
two designs that have been used to investigate the efficacy of con-
tinuation and maintenance treatment with ADMs (cmADMs):
the discontinuation and the extension design (Fig. 1).
In the discontinuation (or placebo-substitution) design, patients
who respond to aADM are randomized to cmADM v. PLA.
Meta-analyses document substantially higher relapse/recurrence
rates during the post-randomization 6–12 months in placebo-
substitution arms (∼42%) compared to the cmAD arms (∼22%)
(Geddes et al., 2003; Glue, Donovan, Kolluri, & Emir, 2010;
Hansen et al., 2008; Kaymaz, van Os, Loonen, & Nolen, 2008).
The major problem of the discontinuation design, however, is
that AD withdrawal symptoms may masquerade as relapse/recur-
rence (Fava, Gatti, Belaise, Guidi, & Offidani, 2015; Greenhouse &
Meyer, 1991). Its bias potential is unclear because of uncertainty
about the risk period of withdrawal phenomena (Borges et al.,
2014; El-Mallakh, Waltrip, & Peters, 1999; Kaymaz et al., 2008).
Excess relapse/recurrence rates in the placebo-substitution arms
compared to the cmADM arms are strongest in the first month
after discontinuation and gradually drop to approximately zero
in the next 3–6 months (Borges et al., 2014; El-Mallakh et al.,
1999; Kaymaz et al., 2008).
Extension trials start as regular double-blind, placebo-
controlled aADM trials that continue blinded treatment in
responders to ADMs (∼45%) and responders to PLA (∼32%)
for another 5–12 months (Zimmerman, Posternak, & Ruggero,
2007). In five double-blind extension trials including 901 partici-
pants and lasting on average 35 weeks, relapse/recurrence rates in
those who initially remitted averaged 25% in the PLA arm v. 8%
in the ADM arm, showing a strong benefit for cADM relative to
cPLA (RR = 2.0) (Zimmerman et al., 2007). The extension design
lacks the withdrawal issues of discontinuation trials, but still has
the limitation that acute phase non-responders are not included
and followed. This is a serious limitation as about half do not
remit on acute phase treatment (Khin, Chen, Yang, Yang, &
Laughren, 2011; Levkovitz et al., 2011; Pigott, Leventhal, Alter,
& Boren, 2010; Rush et al., 2006). Treatment completion rates
were often <50%.
In conclusion, compared to discontinuation trials, extension
trials provide stronger evidence that cmADM in responders to
aADM treatment reduce relapse/recurrence risk relative to
cmPLA in aPLA responders because aADM responders were
not switched to PLA, excluding confounding effects of ADM
withdrawal. However, extension trials are relatively rare and
patients on cmPLA, although they initially responded, may slowly
realize that they are using placebos, with possibly negative psycho-
logical consequences.
Naturalistic long-term outcome studies
Many naturalistic outcome studies (i.e. non-randomized observa-
tional cohort or longitudinal studies) have charted the long-term
course and outcome of depression (⩾2 years). Reviews typically
report worse long-term outcomes for depressed patients who
are managed in specialty settings compared to those managed in
primary care (e.g. Brodaty, Luscombe, Peisah, Anstey, & Andrews,
2001; Hardeveld, Spijker, De Graaf, Nolen, & Beekman, 2010;
Piccinelli & Wilkinson, 1994; Steinert, Hofmann, Kruse, &
Leichsenring, 2014; van Weel-Baumgarten, Schers, van den Bosch,
van den Hoogen, & Zitman, 2000). Piccinelli and Wilkinson,
reviewing 50 outcome studies, reported weighted averages of 43%
sustained recovery and 15% persistent depression at 1-year
follow-up, and 24% sustained recovery and 12% persistent depres-
sion at >10-year follow-up. Other reviews report recurrence rates
of up to 85% in 15 years for depression treated in specialty settings
(Hardeveld et al., 2010; Mulder & Frampton, 2014). In contrast, two
major reviews of adult depression in general practice and the com-
munity (20 studies of almost 6000 participants, most with 3–7
years follow-ups) found that although 10–17% had a chronic course,
up to 85% recovered for some time and that 35–60% experienced
Psychological Medicine 3
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0033291719003295
Downloaded from https://www.cambridge.org/core. University of Groningen, on 06 Dec 2019 at 11:55:27, subject to the Cambridge Core terms of use, available at























roningen, on 06 D
ec 2019 at 11:55:27, subject to the Cam
bridge Core term
s of use, available at
stable recovery (Steinert et al., 2014; van Weel-Baumgarten et al.,
2000). Regarding outcome of non-treated community and general
practice cases, multiple studies suggest that many depressive epi-
sodes (80–50%) are self-limiting as they remit within 3–12 months
(Goldberg, Privett, Ustun, Simon, & Linden, 1998; Regier et al.,
1998; Sareen et al., 2013; Spijker et al., 2002; Wang et al., 2017;
Whiteford et al., 2013). For instance, Whiteford’s (2013) meta-
analysis of 19 studies of untreated depression in general practice set-
tings estimated that 23% remit within 3 months, 32% within 6
months, and 53% within 12 months.
Observational studies typically report similar or worse out-
comes for treated v. untreated depressive episodes in primary
care and community samples (Boerema et al., 2017; Goldberg
et al., 1998; Hughes & Cohen, 2009; Wang et al., 2017). Hughes
and Cohen’s review compared AD-treated cases in 12 naturalistic
cohorts of treated patients (n = 3901 at final follow-up) and three
non-ADM-treated samples of 1160 patients. Most participants
were white females with one inpatient stay. Frequency, duration,
and severity of episodes varied substantially. Outcomes were unre-
lated to treatment status, and not better in ADM-treated cohorts
relative to non-ADM-treated samples. Heterogeneity of study
designs and outcome definitions were large and hampered statis-
tical analysis. Recent naturalistic long-term outcome studies com-
paring ADM-treated and untreated individuals with diagnosed
depression consistently corroborate the findings of Hughes and
Cohen’s review (Bockting, Hollon, Jarrett, Kuyken, & Dobson,
2015; Hengartner, Angst, & Roessler, 2018; Nuijen, ten Have,
Tuithof, van Dorsselaer, & van Bon-Martens, 2014; Verduijn
et al., 2017; Vittengl, 2017; Wang et al., 2017). Statistical adjust-
ment for confounders (e.g. educational level, marital status, base-
line severity, family history) did not attenuate the association of
ADM treatment with outcome (Hengartner et al., 2018; Vittengl,
2017). However, statistical adjustment cannot adjust for unmeas-
ured differences between ADM v. non-ADM (known as confound-
ing by indication) and it is very likely that untreated cases with
established major depressive disorder are less vulnerable and
more resilient than treated cases (e.g. Goldberg et al., 1998;
Ormel, Oldehinkel, Brilman, & van den Brink, 1993).
Conclusion naturalistic studies
We want to emphasize two points. First, RCTs are the gold stand-
ard of treatment evaluation and naturalistic outcome studies can
never prove treatment (non-) effectiveness relative to no treat-
ment. However, because naturalistic outcome studies typically
do not find an association between ADM-treatment and long-
term outcome, their findings offer ammunition to critics to
express doubts regarding long-term ADM effects, in particular
in combination with (i) the limitations of and (ii) the weaker evi-
dence of prolonged aADM trials. Second, naturalistic long-term
outcome studies typically follow prevalent cases without distin-
guishing between first-ever onset cases v. recurrent cases. As the
latter are overrepresented in patient series and population sam-
ples, they may not reflect the prognosis of first-ever onsets,
which is reasonably positive, with 50–60% achieving stable recov-
ery, 35–40% experiencing at least one recurrence in the next 15
years, and 15% becoming chronic (Eaton et al., 2008; Mattisson,
Bogren, Horstmann, Munk-Jorgensen, & Nettelbladt, 2007).
Efficacy and limitations of psychological treatments
Critics of ADMs often advocate psychological treatments, espe-
cially cognitive behavioral therapy (CBT), interpersonal therapy
(IPT), mindfulness-based cognitive therapy (MBCT), and
problem-solving therapy (PST). But how efficacious are these
treatments and do they offer a serious alternative to cmADM or
are they vulnerable to similar criticisms as the ADM?
Compared to PLA, care-as-usual (CAU), and waiting-list controls,
meta-analyses indicate that short-term efficacy of psychological
treatments is modest in magnitude and comparable to aADM
(e.g. Barth et al., 2013; Cuijpers et al., 2014; Cuijpers, Cristea,
Karyotaki, Reijnders, & Huibers, 2016). For instance, Barth’s
meta-analysis identified 198 studies, including 15 118 adult
patients with depression. All major types of psychotherapeutic
interventions were superior to waitlist control condition with
moderate-to-large effects (range d = 0.62–0.92). Studies with lar-
ger samples and higher quality (blinded observers, self-report
measures, adequate concealed allocation, etc.) reported substan-
tially smaller effects of about d = 0.30. Cuijpers et al.’s
meta-analysis of CBT for MDD, the most studied psychological
treatment, including 63 studies and approximately 4000 partici-
pants, reported a pooled effect size of 0.75 (95% CI 0.64–0.87;
NNT = 3.9). High-quality studies using CAU as a control had sig-
nificantly smaller effect sizes (0.43, NNT 7.3) and so did trials
using PLA as the control (0.55, NNT = 5.5). Direct comparisons
between ADM and major psychological treatments indicate that
they are about equally efficacious in the short-term treatment of
major depression (Cuijpers et al., 2013a, 2013b), although an earl-
ier meta-analysis found a slight excess benefit for SSRIs (Cuijpers,
van Straten, van Oppen, & Andersson, 2008). Dropout rates are
typically smaller in psychological treatments (Cuijpers et al.,
2008). Similar to ADM trials, accumulating biases have also
resulted in overestimation of the short-term efficacy of psycho-
logical treatments,(Cuijpers et al., 2016; Driessen, Hollon,
Bockting, Cuijpers, & Turner, 2015).
Three meta-analyses examined relapse/recurrence in respon-
ders to psychological treatments (largely CBT, BA, and IPT)
(Cuijpers et al., 2013a; Sim et al., 2016; Vittengl, Clark, Dunn,
& Jarrett, 2007). Vittengl et al.’s meta-analysis of 28 studies
including 1880 adults found substantial levels of symptom return
after discontinuation of aCBT in CBT responders (29% within 1
year and 54% within 2 years). These rates appeared comparable
to those associated with other depression-specific psychotherapies
but lower than those associated with aADM. Seven trials com-
pared aCBT and aADM. Averaging separately by treatment type
yielded relapse/recurrence rates of 39% for aCBT and 61% for
aADM over an average of 68 weeks.
Cuijpers et al.’s (2013b) meta-analysis examined the long-term
(6–18 months) effects of aCBT v. aADM with and without
cmADM (nine studies, 506 patients) (Cuijpers et al., 2013b).
Short-term outcomes were comparable although dropout was
lower in CBT. Patients who received acute phase CBT were signifi-
cantly less likely to relapse after discontinuation than patients who
were withdrawn from ADM (OR = 2.61, 95% CI 1.58–4.31, NNT
= 5). There was a non-significant trend favoring prior CBT over
acADM (five studies) ( p < 0.1; OR = 1.62, 95% CI 0.97–2.72;
NNT = 10) ( p < 0.1; OR = 1.62, 95% CI 0.97–2.72; NNT = 10);
suggesting that aCBT might be even more efficacious than con-
tinuation ADM in preventing relapse. Finally, Sim et al.’s
meta-analysis included 22 psychosocial treatment trials [CBT,
IPT, MBCT, psychoeducation that followed 1969 (mostly) remitted
patients with recurrent depression across 24 months (Sim et al.,
2016)]. Treatments were slightly more effective than controls in
preventing relapse/recurrence: pooled RR = 1.39 (1.13–1.70); sub-
stantially less effective than in Vittengl et al.’s meta-analysis.
Psychological Medicine 5
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Some trials have recently examined whether preventive var-
iants of CBT/MBCT have better long-term outcomes than
cmADM. These trials randomized aADM responders into two
or three arms: continuing ADM v. preventive CBT/MBCT with
or without continuing ADM (Bockting et al., 2018; Huijbers
et al., 2016; Kuyken et al., 2015; Segal et al., 2010). A recent
meta-analysis of four preventive MBCT trials (637 participants,
266 relapses during the 60-week follow-up period) found a statis-
tically significant advantage for MBCT compared to cmADM,
suggesting that MBCT appears efficacious as a treatment for
relapse prevention for those with recurrent depression in (partial)
remission (Kuyken et al., 2016). Additionally, in a recent trial not
included in that review, cmADM was not superior to preventive
CT administered while tapering off ADM [relapse/recurrence
risks over 15–24 months (60% v. 63%) (Bockting et al., 2018)].
However, tapering was often unsuccessful as many patients con-
tinued or resumed cmADM, which may have decreased symptom
return in the taper PCT/MBCT arm. On the other hand, misclas-
sified withdrawal symptoms may have increased symptom return
in this arm.
Conclusions
Although these findings suggest that acute phase and preventive
psychotherapy represent viable alternatives to ADM treatment,
the evidence is still somewhat uncertain due to the relatively
small number of high-quality trials and the inherent problem of
blinding in psychotherapy evaluation. Currently, the evidence
base of cmADM in acute phase ADM responders is substantially
larger than that for recurrence-prevention using CBT/MBCT,
which may reflect registration requirements and funding oppor-
tunities. Similar to ADM trials, accumulating biases have also
resulted in overestimation of the short- and long-term efficacy
of psychological treatments (Cuijpers et al., 2016; Driessen
et al., 2015). Effective blinding remains a problem and waitlist
controls are often used even though this is known to inflate con-
trasts (Cuijpers & Cristea, 2015). Furthermore, in all trials com-
paring psychological treatments with discontinued ADM,
misclassified withdrawal symptoms in the ADM arm may have
inflated the difference. Hence, there is a clear need for replication
by high-quality head-to-head trials.
How to resolve the controversy
New data are urgently needed to push the (partly political) anti-
depressant debate toward a balanced and evidence-based discus-
sion of benefits and harms of treatment modalities. We
recommend four approaches: (1) placebo-controlled RCTs with
relevant long-term outcomes, (2) analysis of non-randomized
treatment outcome data using instrumental variable analysis
and propensity score analysis, (3) patient cohort studies including
effect moderators to enhance personalized treatment, and (4) psy-
chological interventions as a universal first-line treatment step.
The first two approaches will inform regarding treatment effects
on long-term outcome whereas the latter two will reduce the rele-
vance of the controversy. Negotiations between advocates and
critics of AD to achieve consensus on the exact data needed to
resolve the controversy should precede concrete research steps.
Placebo-controlled trials with relevant long-term outcomes
Logistically extremely difficult but in our opinion highly desirable
are randomized placebo-controlled long-term outcome studies of
ADM and psychotherapy. Long-term means at least 1 year
follow-up, preferably 2 years. If sufficiently powered, an additional
arm of combined treatment (COM) could be added. An example
of a top priority trial is randomization of currently ADM-free
depressed individuals, stratified by history of ADM treatment
(never v. ever), to ADM v. CBT v. PLA. Acute phase non-
responders, irrespective of treatment, will be offered the treatment
they prefer, but kept in the study and administered the very same
follow-up assessments, thereby addressing the major deficiency of
previous trials. Alternatively, non-responders could be offered the
other treatment modality in addition to the allotted treatment
(COM) and provide the same for the PLA non-responders.
Primary outcomes should be psychopathology, role function,
adverse events, and acceptability. Machine learning can be used
to generate selection algorithms that identify the optimal inter-
vention for each individual who does not remit on COM and
use those algorithms in the patient by mechanism interactions
to improve the power of the tests of mediation (Cohen &
DeRubeis, 2018). If putative effect moderators are included at
baseline, much can be learned about interactions between treat-
ment modality and effect moderators. Finally, it is important to
perform cost-effectiveness analyses as well because what drives
shifts in practice are often shifts in reimbursement and what
drives shifts in reimbursement is evidence of cost-effectiveness.
As an anonymous program officer at NIMH once said: ‘You can-
not herd cats but you can move their food.’
Multiple problems threaten the feasibility and validity of the
proposed study: dropouts, protocol violations, imbalance between
the arms at the entry of the continuation phase, complex logistics,
and ethical concerns. Since 2000, it has been difficult to keep
patients on PLA for more than a few months because it is consid-
ered unethical to withhold effective treatment. However, the
modest excess efficacy of ADM and CBT relative to PLA implies
that the majority of patients who respond to specific treatments
do so for other reasons; that is, due to non-specific treatment
effects and spontaneous remission, and not a ‘specific’ ADM or
CBT effect. Furthermore, ethical concerns are manageable using
patient-level stopping rules. The modest net efficacy of ADM or
CBT (specificity) reduces the threat of imbalance as well, as
many will respond to PLA, and balance can be managed with pro-
pensity analyses. Logistical problems necessitate the cooperation
of many primary care providers from large catchment areas.
Inventive analyses of observational databases
The unsurpassed advantage of randomization is that the resulting
groups are comparable (apart from differences due to chance). This
allows the unambiguous attribution of differences in outcomes
between groups to differences in treatment. Observational, non-
randomized research can never rule out that the groups differ in
characteristics (confounders) that affect both treatment and out-
come. Notorious ‘confounders’ are severity and history. However,
statisticians have recently developed methods that allow, under
certain conditions and with reasonable certainty, causal state-
ments about treatment effects based on observational data, even
if not all potential ‘confounders’ are measured. The methods
are instrumental variable analysis (Martens, Pestman, de Boer,
Belitser, & Klungel, 2006) and propensity score analysis (Austin,
2011). Potentially relevant observational databases can be gener-
ated from routine outcome measurement (ROM), patient cohort
data, and longitudinal population-based studies, provided they
assess long-term outcome.
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Cohort studies including effect moderators
Predicting who will benefit from which treatment is difficult. As a
result, personalized treatment (‘precision medicine’) is not yet
possible with depression although there are interesting develop-
ments in this direction (Cohen & DeRubeis, 2018; DeRubeis
et al., 2014; Fournier et al., 2009; Kessler, 2018). Cohort studies
of patients with the same diagnosis can provide insight if putative
effect moderators are included at baseline. If treatments become
more precise and personalized, the relevance of the ADM contro-
versy will decline. Relatively easy to measure potential effect mod-
erators are clinical characteristics, personality, biomarkers to be
determined from bodily fluids including DNA, social network,
and support characteristics.
Psychological help as a first-line treatment
An approach that may also reduce the relevance of the contro-
versy as well is to offer short-term psychological treatment as
the first-line treatment step for all patients with depression unless
they refuse or cannot receive psychological treatment or have
characteristics shown to predict a better response to ADM.
ADM then remains reserved for patients who do not want, get,
or respond to this first step. It is of great importance which of
the non-responders to psychological treatment improves on
ADM and whether psychological treatment can subsequently
contribute to the phasing out of their ADM use. Severely ill
patients could be started on combination of ADM and psycho-
therapy. Some guidelines actually do advise psychological treat-
ment for adolescents with depression as the first-line treatment
step, and other guidelines, such as the UK NICE guideline for
depression and the Dutch multidisciplinary guideline for depres-
sion, also recommend psychological treatment as the default first
step for adults with mild-to-moderate depression(Clark, 2018;
NICE, 2011; Spijker et al., 2019).
Concluding comments
The ADM debate lingers because of mixed messages and differ-
ences between ADM critics and advocates in their interpretations
of the research findings, the weaknesses and strengths of the vari-
ous studies, and the lack of high-quality RCTs with long-term
follow-ups; not a single large trial investigated head-on the long-
term outcomes of acute phase CBT v. ADM v. PLA. The problems
of generalizability to real-world patients, unblinding, dropout,
withdrawal symptoms, exclusion of acute phase non-responders,
selective reporting, and publication bias make it easy for critics
and advocates to minimize the relevance of study findings that
do not fit their interests and beliefs and emphasize the relevance
of findings that do fit. It is worth noting that these problems affect
both psychotherapy and ADM. What also plays a role is that we do
not fully understand what depression is, or what the precise mech-
anism of action of ADM is. The combination of multiple theories
with little substrate is not helping to resolve the controversy.
Overall, relatively strong evidence (in terms of low bias risk) in
favor of ADM relative to PLA comes from the ‘classical’ trials with
relatively long follow-ups (6–8 months) and the extension studies
targeting relapse in responders to acute phase ADM v. PLA.
However, the extension studies are limited to acute phase respon-
ders and the ‘classical’ trials are few in number and show statistic-
ally significant associations only for response and not remission.
This suggests that long-term follow-up effects of ADM may be
smaller than 8-week post-treatment effects; control groups tend
to ‘catch up’ with the treatment group across time.
It is likely to prove especially important to conduct cost-
effectiveness analyses of these studies. With the advent of the
SSRIs, the pendulum has swung toward a wholesale reliance on
ADM with the vast majority of the prescriptions now written in
general practice. The UK has bucked this trend by bypassing
the providers and going straight to the funders in the government
with relevant cost-effectiveness data (Clark, 2018). The National
Health Service invested £700 million pounds to train psychothera-
pists to do interventions judged to be efficacious in clinical prac-
tice guidelines developed by the National Institute for Health Care
Evaluation (NICE). Patient outcomes are monitored at every ses-
sion and anonymized aggregate data posted on a publically
accessible website. That recovery rates have risen from 35% to
over 50% across the last decade speaks to the power of shifting
reimbursement to the most cost-efficient interventions and mon-
itoring outcomes in a wholly transparent fashion speaks to the
utility of this English Improving Access to Psychological
Therapies (IAPT) program (Clark, 2018). Although the overall
outcomes achieved by IAPT until 2017 are encouraging, it is
unclear to what extent gains are maintained as systematic long-
term FU are lacking. Hence, it is important to wait for the final
evaluation of the IAPT program.
Despite countless studies on the short-term effectiveness of
ADMs and hundreds of billions of revenue, the ADM debate con-
tinues. The lack of long-term outcome information hampers a
balanced consideration. RCTs comparing the long-term outcome
of ADM v. PLA and psychological treatments can provide the
necessary data. Research consortia with researchers from varied
fields and different allegiances are best situated to perform such
‘mega-trials’ so as to guarantee balanced composition (Quitkin
et al., 2000) in accordance with the principle of ‘adversarial col-
laboration’ (Mellers, Hertwig, & Kahneman, 2001). Given the
substantial prevalence of depression and cmADM treatment
and the availability of alternative treatments, it is crucial that
the lacking data become available.
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